COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,009 Articles (22,627 medRxiv, 8,382 bioRxiv)

Most recent first Previous |  Page 492: Articles 4911-4920  | Next

Vectored Immunoprophylaxis and Treatment of SARS-CoV-2 Infection
Tada, T., Dcosta, B. M., Minnee, J., Landau, N. R.
10.1101/2023.01.11.523649 — Posted: 2023-01-12
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Vaca, G. B., Meyer, M., Cadete, A., Hsiao, C. J., Golding, A., Jeon, A., Jacquinet, E., Azcue, E., Guan, C. M., Sanchez-Felix, X., Pietzsch, C. A., Mire, C. E., Hyde, M. A., Comeaux, M. E., Williams, J. M., Sung, J. C., Carfi, A., Edwards, D. K., Bukreyev, A., Bahl, K.
10.1101/2023.01.11.523616 — Posted: 2023-01-12
DISPOSITION OF ADOLESCENTS TOWARD RECEIVING COVID-19 VACCINATIONS IN VILLAVICENCIO: MYTHS AND BELIEFS
Garcia Balaguera, C., Alfonso, M. F., Echavarria, M. P., Pardo, M. C.
10.1101/2023.01.10.23284415 — Posted: 2023-01-12
Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma: A Systematic review and meta-analysis
Senefeld, J., Gorman, E. K., Johnson, P., Moir, M. E., Klassen, S. A., Carter, R. E., Paneth, N. S., Sullivan, D. J., Morkeberg, O. H., Wright, R. S., Fairweather, D., Bruno, K. A., Shoham, S., Bloch, E. M., Focosi, D., Henderson, J. P., Juskewitch, J. E., Pirofski, L.-a., Grossman, B. J., Tobian, A. A., Franchini, M., Ganesh, R., Hurt, R. T., Kay, N. E., Parikh, S. A., Baker, S. E., Buchholtz, Z. A., Buras, M. R., Clayburn, A. J., Dennis, J. J., Diaz Soto, J. C., Herasevich, V., Klompas, A. M., Kunze, K. L., Larson, K. F., Mills, J. R., Regimbal, R. J., Ripoll, J. G., Sexton, M. A., Shepherd, J. R., Stubbs, J. R., Theel, E. S., van Buskirk, C. M., van Helmond, N., Vogt, M. N., Whelan, E. R., Wiggins, C. C., Winters, J. L., Casadevall, A., Joyner, M. J.
10.1101/2023.01.11.23284347 — Posted: 2023-01-12
COVID-19 NFL Injury Prevalence Analysis, A Follow-Up Study
Puga, T. B., Schafer, J., Thiel, G., Scigliano, N., Ruan, T., Toledo, A., Agbedanu, P. N., Treffer, K.
10.1101/2023.01.11.23284292 — Posted: 2023-01-12
Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France
Tamandjou, C., Auvigne, V., Schaeffer, J., Vaux, S., Parent du Chatelet, I.
10.1101/2023.01.11.23284137 — Posted: 2023-01-12
The Smoldering Pandemic: Self-Reported Prevalence Assessment of Prolonged Grief Disorder. A cross sectional study of bereaving adults during the Covid Pandemic in Pakistan.
Siddiqua, A., Ahmad, S., Zeeshan, D. M., Nawaz, I., Rao, A.
10.1101/2023.01.10.23284300 — Posted: 2023-01-11
ADAPTIVE TIME LOCATION SAMPLING FOR COMPASS, A SARS-COV-2 PREVALENCE STUDY IN FIFTEEN DIVERSE COMMUNITIES IN THE UNITED STATES
Zangeneh, S. Z., Skalland, T., Yuhas, K., Emel, L., Tapsoba, J. D. D., Reed, D., Amos, C., Donnell, D., Moore, A., Justman, J.
10.1101/2023.01.10.23284400 — Posted: 2023-01-11
Exosome based multivalent vaccine: achieving potent immunization, broaden reactivity and T cell response with nanograms of proteins without any adjuvant.
Cacciottolo, M., Nice, J. B., Li, Y., LeClaire, M. J., Twaddle, R., Mora, C. L., Adachi, S. Y., Chin, E. R., Young, M., Angeles, J., Elliott, K., Sun, M.
10.1101/2023.01.10.523356 — Posted: 2023-01-11
Impact of COVID-19 pandemic on cancer screening in Denmark: A register-based study
Nonboe, M. H., Napolitano, G., Schroll, J. B., Vejborg, I., Waldstroem, M., Lynge, E.
10.1101/2023.01.03.22277971 — Posted: 2023-01-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).